[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.124.106. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
June 2013

Patient Blood ManagementKey for Accountable Care Organizations

Author Affiliations

Author Affiliations: New York Blood Center (Drs Shaz and Hillyer) and Weill Cornell Medical College (Dr Hillyer), New York; Emory University School of Medicine, Atlanta, Georgia (Dr Shaz); and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (Dr Waters).

JAMA Surg. 2013;148(6):491-492. doi:10.1001/jamasurg.2013.69

Blood products and their transfusion represent significant expense to hospitals. As health care systems look toward more affordable, higher-quality care, better management of our blood supply offers significant opportunity to contribute to these goals. Audits have demonstrated that 15% to 30% of blood products are used outside of evidence-based guidelines.1 A recent JAMA article2 demonstrated hospital variability in blood use in adult cardiac surgery; rates of transfusion ranged from 7.8% to 92.8% for red cells, 0% to 97.5% for plasma, and 0.4% to 90.4% for platelets. This high variability reflects the variability that exists in health care overall, for instance, variability in surgical approach to total hip replacement (1-hole minimally invasive approach or 2-hole minimally invasive approach vs open approach); thrombosis prophylaxis (warfarin or aspirin vs low-molecular-weight heparin); anesthetic management (general anesthesia or spinal anesthesia vs peripheral nerve blocks); and how surgeons perform transfusions in their patients. Additionally, allogeneic transfusion has been associated with increased infection rates, length of stay, and mortality,3 although these outcomes may relate to other factors.

First Page Preview View Large
First page PDF preview
First page PDF preview
×